Table I.

Demographic and clinical characteristics of patients who were treated with high-dose AZT–MTX alone or in combination with dose dense regimens.

Age	Sex	HIV	HIV- lymphoma*	Lymphoma type	PS	CD4	LDH	Stage	Ki-67 (%)	Extranodal sites	Number of AZT– MTX cycles	Alternating chemotherapy with AZT–MTX and no. of cycles	RT	Adverse events (grade ≥ 3)	Response†	Survival†
34	M	+	1	LCL	3	4	1359	IVB	50	Lung, CNS	2	---	−	NF, T	Not evaluable	Hospice
51	F	+	14	LCL	2	47	11 506	IVB	---	Stomach	3	EPOCH x3	−	---	CR (95)	Alive (95)
49	M	+	0	BL	2	91	4601	IVB	---	BM	3	EPOCH x1	−	---	CR (77)	Alive (77)
40	F	−	NA	BL	2	---	3155	IIA	100	---	2	hCVADx3	+	---	CR (87)	Alive (87)
40	M	+	0	BL	2	214	3424	IVB	95	OSM	2	hCVADx1	−	---	PD	Dead (9)
34	M	+	9	PBL	2	16	689	IVB	96	OSM	1	---	−	Diarrhea, mucositis	PD	Dead (4)
33	F	+	13	PBL	1	166	418	IIA	---	OSM	3	EPOCH x3	−	---	CR (42)	Alive (42)
44	M	+	0	PBL	1	458	470	IVA	100	Bone, OSM	3	EPOCH x3	−	---	CR (46)	Alive (46)
52	M	+	0	PBL	1	57	1005	IIB	95	OSM	4	EPOCH x4	+	---	CR (49)	Alive (49)
51	M	+	20	Solid PBL	2	113	710	IVB	---	Pericardium, OSM	4	---	−	---	CR (31)	Alive (68)

PS, Eastern Cooperative Oncology Group performance score; LDH, serum lactate dehydrogenase level at diagnosis (normal range 313 – 618 U/L); MTX, methotrexate; AZT, zidovudine; RT, radiotherapy; NA, not available; LCL, large cell lymphoma; PEL, primary effusion lymphoma; PBL, plasmablastic lymphoma; CNS, central nervous system; BM, bone marrow; OSM, orosinusoidal mucosa; EPOCH, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; hCVAD, hyperfractionated cyclophosphamide with vincristine, doxorubicin and dexamethasone; NF, neutropenic fever; T, thrombocytopenia; CR, complete remission; PD, progressive disease.

^*Interval between human immunodeficiency virus (HIV) and lymphoma diagnosis in years.

^†Duration in months in parentheses.